doxorubicin hydrochloride

Primary breast double-hit lymphoma is a very rare, highly aggressive malignancy that presents a great challenge regarding proper diagnosis and optimal treatment. Our case involved high-grade B-cell lymphoma with MYC and BCL2 rearrangement (double hit), treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin chemotherapy, resulting in complete resolution.

Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy.

The patient was subsequently treated with DA-EPOCH chemotherapy (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), leading to significant regression of disease on interim PET scan. This case represents the 10th reported transformation of MM to PBL and highlights the diagnostic dilemma posed by these entities. It underscores the importance of clinical context, the potential for clonal evolution (evidenced by a light-chain switch), and the efficacy of lymphoma-specific chemotherapy in this setting.

Collectively, these findings establish cysteine depletion as an early redox feature of DOX cardiotoxicity and demonstrate that cysteine-targeted redox imaging enables mechanism-guided discovery of cardioprotective agents. This study highlights gnetol as a promising ferroptosis-suppressing candidate and provides a mechanistic framework for early detection and intervention in redox-driven cardiac injury.

Among the synthesized series, compound 8g exhibited the highest potency, with IC₅₀ values of 3.93 μM, 9.56 μM, and 6.30 μM against HepG2, PC-3, and HCT-116, respectively, surpassing the reference drugs doxorubicin (4.50 μM against HepG2) and sorafenib (9.18 μM against HepG2). Mechanistically, 8g demonstrated strong inhibition of VEGFR2 (IC₅₀ = 0.38 μM), but it outperformed PD-L1 inhibition compared to Bavencio (IC₅₀ = 134.41 pg/mL and 217.74 pg/mL, respectively)...In silico molecular docking and dynamic simulation assisted data strongly correlated with the experimental approach that compound 8g exerts multi-targeted anticancer activity via VEGFR2 and PD-L1 inhibition. In conclusion, 8g is a promising candidate recommended for further therapeutic development.

P2, N=50, Recruiting, Ou Bai, MD/PHD

The rationally designed G4 module enables three synergistic functions encompassing enhanced CpG nuclease resistance for sustained TLR9 pathway activation, site-specific loading of doxorubicin (DOX) to trigger potent immunogenic cell death (ICD) and release tumor antigens, and IMT anchoring to activate the cGAS-STING pathway...In murine 4T1 breast cancer models, IONP-G4-DOX/IMT achieves a primary tumor suppression rate of approximately 79.4%, with no significant systemic toxicity. More importantly, it elicits potent long-term antitumor immunity that inhibits contralateral tumor growth, offering a versatile and promising strategy for advanced abscopal chemoimmunotherapy.

The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. Subclinical cardiac dysfunction was common but mild and manageable. These findings provide further support for its use in neoadjuvant settings with appropriate monitoring strategies, especially in real-world clinical settings with variable access to monitoring resources.

The effects of ultrasound-enhanced drug delivery to HepG2 cells demonstrated that the combination of ultrasound and targeted liposomes significantly increased the internalization of the drug (DOX) and triggered apoptosis in HepG2 cells, leading to cell death. Morphological observations on treated cells via phase contrast microscopy supported the signs of apoptosis, indicating LL's potential to target liver cancer cells effectively.

The CRISPR-magnetic microbots were constructed by engineering CRISPR/Cas12a and DNA icosahedra/doxorubicin (DNA-ICOS/DOX) on intracellularly gelated magnetic cells (IGMCs)...Therefore, by combining the CRISPR-magnetic microbots with the dual-target-guided orthogonal barcoding strategy in a homogeneous electrochemical biosensor, precise identification and sensitive detection of tEVs were successfully achieved. More significantly, this assay achieves accurate cancer subtyping in clinical samples, demonstrating its potential as a robust, noninvasive tool for high-accuracy disease screening, classification, and progression monitoring.

Surgical resection and cervicothoracic fixation were performed, followed by radiotherapy (30 Gy/10 fractions) and Ewing-based chemotherapy (doxorubicin/ifosfamide). Local recurrence occurred despite multimodal therapy. This case highlights the clinical and diagnostic challenges associated with EWSR1-rearranged non-ETS sarcomas, which exhibit distinct molecular behaviors, morphology, and treatment responses compared to classical Ewing sarcoma.

After the operation, the patient was treated with vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide chemotherapy, which resulted in a partial radiological response. This case illustrates the diagnostic difficulties associated with intracranial ES due to its radiological similarity to meningioma and stresses the importance of immunohistochemical and genetic analysis for a conclusive diagnosis. Early multimodal management is vital for improving survival in such rare cases.